false 0001785530 0001785530 2024-05-24 2024-05-24

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 24, 2024

 

 

WEREWOLF THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40366   82-3523180

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

200 Talcott Avenue, 2nd Floor  
Watertown, Massachusetts   02472
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 952-0555

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   HOWL   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

At the annual meeting of stockholders of the Company held on May 24, 2024, the Company’s stockholders voted on the following proposals:

(a) The stockholders of the Company elected Michael Atkins, M.D., Luke Evnin, Ph.D., and Alon Lazarus, Ph.D. as Class III directors, each for a three-year term ending at the annual meeting of stockholders to be held in 2027. The results of the stockholders’ vote with respect to the election of the Class III directors were as follows:

 

Name

  

Votes For

  

Votes

Withheld

  

Broker

Non-Votes

Michael Atkins, M.D.

   31,566,857   19,721   5,145,182

Luke Evnin, Ph.D.

   20,732,054   10,854,524   5,145,182

Alon Lazarus, Ph.D.

   31,503,628   82,950   5,145,182

(b) The stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of the stockholders’ vote with respect to such ratification were as follows:

 

For

  

Against

  

Abstain

36,686,933   41,889   2,938

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    WEREWOLF THERAPEUTICS, INC.
Date: May 28, 2024     By:  

/s/ Jonathan Owen

      Jonathan Owen
      Secretary
v3.24.1.1.u2
Document and Entity Information
May 24, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001785530
Document Type 8-K
Document Period End Date May 24, 2024
Entity Registrant Name WEREWOLF THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-40366
Entity Tax Identification Number 82-3523180
Entity Address, Address Line One 200 Talcott Avenue
Entity Address, Address Line Two 2nd Floor
Entity Address, City or Town Watertown
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code (617)
Local Phone Number 952-0555
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol HOWL
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
Werewolf Therapeutics (NASDAQ:HOWL)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Werewolf Therapeutics Charts.
Werewolf Therapeutics (NASDAQ:HOWL)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Werewolf Therapeutics Charts.